Indian Generic Drug Firm Ranbaxy Announces Joint Venture With South African Firm To Sell ARVs in Africa
India-based generic drug company Ranbaxy Laboratories on Monday announced it had entered a joint venture with the South Africa-based firm Community Investment Holdings to sell Ranbaxy's antiretroviral drugs in Africa, Reuters reports (Reuters, 2/6). Ranbaxy South Africa CEO Desmond Brothers said the venture will allow the company to sell its drugs at a low cost. Ranbaxy will hold 70% of the venture, named Sonke Pharmaceuticals, which will sell products under the trademark "Sonke" (Dow Jones, 2/6). Products will be available through governments, retail pharmacists, HIV/AIDS disease management companies, nongovernmental organizations and independent community treatment organizations in South Africa, Botswana and Namibia, Ranbaxy said in a release (AP/Houston Chronicle, 2/6).This is part of the KHN Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.